Physician profile
Jason D Munitz
NPI 1215952395
$2,237.37
in general payments reported to CMS, 2019-2025
24 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $81.87 · 2021: $165 · 2022: $241 · 2023: $323 · 2024: $386 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synergeyes, INC. | $520.76 | 2019 | |
| Dompe US, INC. | $335.25 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $279.86 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $129.58 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $95.03 | 2019-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $89.40 | 2019-2024 | |
| Coopervision INC. | $83.82 | 2019-2023 | Myday Contact Lens |
| Alcon Vision LLC | $79.53 | 2019-2025 | Tryptyr, Rocklatan |
| Astellas Pharma US INC | $76.85 | 2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $71.41 | 2021-2023 | Acthar |
| Biotissue Holdings INC. | $68.41 | 2021-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.63 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $48.56 | 2022-2025 | Iluvien |
| Oyster Point Pharma, INC. | $47.02 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $41.01 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.99 | 2021 | |
| Harrow Eye, LLC | $34.77 | 2024-2025 | Iheezo, Vevye |
| Abbvie INC. | $32.37 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $27.89 | 2019-2022 | |
| Genentech USA, INC. | $22.08 | 2025 | Vabysmo |
| Rxsight INC | $17.61 | 2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Apellis Pharmaceuticals, INC. | $17.03 | 2024 | Syfovre |
| Horizon Therapeutics Plc | $14.06 | 2019 | |
| Visioneering Technologies, INC. | $10.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Munitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.